Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Nanoparticles have emerged as one of the most promising drug delivery systems in the field of chemotherapy for localized and
metastasized cancers owing to their unique potentials like high intracellular uptake, enhanced permeability and retention
while reducing undesirable side effects. A number of naturally occurring polyphenols, present in most commonly consumed
beverage tea, has been shown to possess anticancer properties but has associated with limited success including inefficient
systemic delivery and bioavailability under in vivo conditions. Our present work investigated the efficiency of polyphenolic
constituents of black (Theaflavin-TF) and green (epigallocatechins-3-gallate-EGCG) tea encapsulated in poly (lactic-co-glycolic
acid) nanoparticles (NPs) using double emulsion method. The nanoparticles formulated were and then characterized for
encapsulation efficiency, surface morphology, particle size and in vitro release. TEM analysis showed the formation of spherical
and monodisperse nanoparticles, with an encapsulation efficiency of ~18% and 26% for TF and EGCG, respectively. Further their
preventive potential against 7, 12-dimethylbenzanthracene (DMBA) induced DNA damage in mouse skin using DNA alkaline
unwinding assay (DAUA) was evaluated. Pre-treatment (topically) of mouse skin with TF or EGCG (100μg/mouse) doses exhibits
protection of 45.34% and 28.32%, respectively, against DMBA induced DNA damage. Additionally, TF/EGCG loaded NPs have
showed significant potential for induction of DNA repair genes (XRCC1, XRCC1 and ERCC3) and suppression of DNA damage
responsive genes (p53, p21, MDM2, GADD45α and COX-2) as compared to respective bulk doses. Hence, our studies achieved
successful formulation of EGCG and TF loaded PLGA nanoparticles and has high potential to control DMBA induced DNA
damage at much more reduced concentrations and thus opens a new arena for clinical application in prostate cancer therapy.
Biography
Priyanka Bhatnagar has completed her M.Sc. in Chemistry (Organic) from University of Delhi, India in 2009. She is pursuing her Ph.D in Bio-organic
Chemistry from Institute of Genomics & Integrative Biology (IGIB), CSIR Lab, New Delhi, India. She is working in the area of design and development
of Polymeric systems for Effective Drug Delivery. She has 1 paper in reputed journal.
Relevant Topics
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals